Twist Bioscience Launches Exome 2.0 for Genomics Research

By: Twist Bioscience Corporation via Business Wire

October 20, 2021 at 08:00 AM EDT

- Best-in-Industry Exome Content and Performance -

- Enables Lower Sequencing Costs through Best-in-Class Uniformity -

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced the launch of its Exome 2.0, featuring the most comprehensive coverage of protein-coding and noncoding regions of the genome, as well as best-in-class performance to reduce downstream sequencing costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211020005355/en/

Twist Exome 2.0, the most comprehensive coverage of protein-coding and noncoding regions of the genome and best-in-class performance. (Photo: Business Wire)

“We have been working with Twist for the last three years and recently adapted the Twist Exome 2.0 for our recent work for various indications, especially for unexplained developmental disorders,” said Oliver Wachter of the Center for Human Genetics and Laboratory Diagnostics in Germany (MVZ-Martinsried GmbH). “The content, performance and quality are the best we have experienced from any provider, and we didn’t have to choose between robust content and performance.”

“Twist continues to expand our portfolio of high-quality, best-in-class life science tools,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “With the launch of Exome 2.0, we now offer a complete portfolio of flexible, comprehensive exome options to support genomics researchers looking to identify the underpinnings of disease.”

About Twist Exome 2.0

The Twist Exome 2.0 is an exome panel designed with thoughtfully curated content that includes comprehensive coverage of genes responsible for rare diseases, inherited disorders, and germline cancers in humans. With a fully automatable workflow, Twist Exome 2.0 outperformed available exomes on the market today, demonstrating higher uniformity and a higher on-target rate, as well as lower drop out and duplicate read rates, resulting in better data and lower sequencing costs. Exome 2.0 provides best-in-class coverage of protein-coding regions from major genetic databases (RefSeq, CCDS, GenCode, Clinvar, ACMG73 and more) as well as coverage of clinically relevant non-coding pathogenic and likely pathogenic variants. Twist Exome 2.0 can be customized for a wide range of applications and uses, while providing workflow flexibility through Fast Hybridization (<4 hrs) or the new Standard Hybridization v2 (overnight) reagents. All Twist exomes contain double-stranded DNA probes for more complete coverage, can be customized to specific needs, and work with Twist’s library preparation and target enrichment workflows. Twist Exome 2.0 works with the recently launched enzymatic fragmentation 2.0 kit to provide unmatched performance and efficiency in sequencing ready libraries.

To view other Twist library prep solutions, visit: https://www.twistbioscience.com/products/ngs/library-preparation/ngs-library-preparation-kits.

To learn more about Twist Exome 2.0 visit: https://www.twistbioscience.com/products/ngs/fixed-panels/exome2.

About Twist Bioscience Corporation

Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including but not limited to the ability of Exome 2.0 to help identify the underpinnings of disease, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; the retention of employees of acquired companies and the ability of Twist Bioscience to successfully integrate acquired companies and to achieve expected benefits, risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report Form 10-Q filed with the Securities and Exchange Commission on August 9, 2021, and subsequent filings with the SEC. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005355/en/

Contacts

Twist Bioscience

Angela Bitting

SVP, Corporate Affairs

925-202-6211

media@twistbioscience.com

About Us

About Cabling Installation & Maintenance

Contact Cabling Installation & Maintenance

Editorial

Advertising and Sponsorship Sales

Subscriptions and Memberships

Feedback/Problems

Twist Bioscience Launches Exome 2.0 for Genomics Research

Contacts

More News